What are the recommended treatment options for fungal pneumonia in adults?

Treatment of Fungal Pneumonia

For invasive pulmonary aspergillosis, initiate either voriconazole monotherapy or combination therapy with a mold-active triazole plus echinocandin, with voriconazole being the preferred first-line agent in most cases 1.

Invasive Pulmonary Aspergillosis (IPA)

Primary Therapy

• Voriconazole is the drug of choice for initial treatment of proven or probable IPA 1, 2, 3
• The 2025 ATS guideline provides a conditional recommendation allowing either:
  • Mold-active triazole monotherapy (preferred in most cases), OR
  • Initial combination therapy with mold-active triazole plus echinocandin 1

When to Consider Combination Therapy

Combination therapy (triazole + echinocandin) is specifically recommended for:

• Severe, refractory, or treatment-failure IPA 4
• Critically ill patients with sepsis or severe respiratory failure 5
• Options include: triazoles plus echinocandins and/or polyenes, or echinocandins plus polyenes 4

Alternative Agents

• Liposomal amphotericin B (3 mg/kg/day) is the preferred alternative when voriconazole is contraindicated, causes intolerable side effects, or drug interactions preclude its use 3
• Caspofungin is indicated for salvage therapy in refractory disease 2, 5

Adjunctive Measures for IPA

• Bronchoscopy is recommended for early diagnosis, particularly in airway-invasive aspergillosis 4
• Bronchoscopic interventions (injection/spraying of antifungals) can be used for airway-invasive disease 4
• Nebulized antifungal inhalation is recommended when systemic therapy is not feasible or as prophylaxis in high-risk patients 4
• Surgical debridement of necrotic tissue should complement antifungal therapy whenever possible 3

Critical pitfall: Therapeutic drug monitoring of mold-active azoles should be implemented to minimize toxicity and maximize efficacy 3.

Coccidioidomycosis

Uncomplicated Primary Pulmonary Coccidioidomycosis

Most patients (>90%) recover without antifungal therapy 6. However, initiate treatment with fluconazole ≥400 mg daily if:

• Significantly debilitating illness at diagnosis 6
• Extensive pulmonary involvement 6
• Concurrent diabetes 6
• Frail due to age or comorbidities 6
• Some experts include African or Filipino ancestry as indication 6

Treatment duration: 3-6 months or longer depending on clinical response 6. Discontinue when signs, symptoms, inflammatory markers resolve and imaging stabilizes—complete serological resolution is not required 6.

Chronic Cavitary Coccidioidal Pneumonia

For symptomatic chronic cavitary disease, treat with oral azole (fluconazole or itraconazole) 6. Response rates are approximately 55% after 8 months, with both agents showing comparable efficacy 6. Treatment should continue for at least 1 year; symptoms recur in ~30% after discontinuation 6.

For asymptomatic cavities: No antifungal treatment is recommended—there is no evidence that early treatment promotes cavity closure 6.

Pulmonary Mucormycosis

Lipid-based formulations of amphotericin B are the drugs of choice 3. Specifically:

• Liposomal amphotericin B is the elective therapy 5
• Combination antifungal therapy is NOT routinely recommended but can be used for severe infection or inadequate monotherapy response 4

Critical Adjunctive Measures

• Early surgical evaluation is crucial for localized lesions 4
• Local drug infusion via bronchoscopy should be performed in confirmed cases 4
• Local debridement via bronchoscopy by experienced teams for surgical candidates or inoperable patients 4

Pulmonary Cryptococcosis

Standard Treatment

• Fluconazole is first-line for most cases 7
• Lumbar puncture should be performed if neurological symptoms, high serum CrAg titers, or immunocompromised status present 4

Fluconazole-Resistant or Treatment Failure Cases

For severe infection:

• Induction: L-AmB (3-6 mg/kg/day) + 5-FC (100 mg/kg/day) for 4 weeks
• Maintenance: Fluconazole (800 mg/day) or voriconazole 4

For mild-moderate infection or amphotericin B intolerance:

• Voriconazole, posaconazole, or isavuconazole for 6-12 months 4

If L-AmB unavailable:

• Consider 5-FC with fluconazole (800-1200 mg/day) 4

Important caveat: Positive CrAg indicates infection and aids diagnosis, but should NOT be used to assess treatment efficacy or guide drug withdrawal 4.

Candida Pneumonia

Antifungal treatment is NOT recommended for Candida isolated from respiratory samples in non-neutropenic patients—true Candida pneumonia is exceptional in this population 5. Approximately 50% of Candida isolates from respiratory samples represent colonization rather than infection 5.

Pneumocystis Pneumonia (PCP)

Echinocandin monotherapy is NOT recommended for PCP 4.

Treatment approach:

• Severe cases with respiratory failure: Echinocandin combined with SMX-TMP 4
• Second-line when SMX-TMP limited by renal impairment: Echinocandin + SMX-TMP 4
• SMX-TMP treatment failure or intolerance: Consider echinocandin with other second-line agents 4
• Low-dose glucocorticoids: Use early in severe PCP with hypoxemia, but NOT in patients without hypoxemia 4

Prophylaxis Considerations

Prophylaxis should be given for at least 3 weeks in:

• Allogeneic hematopoietic stem cell transplant recipients
• Lung transplant recipients
• Patients with severe granulocytopenia
• High-risk patients receiving high-dose immunosuppressive agents 4

Critical caveat: The 2025 ATS guideline conditionally recommends AGAINST routine prophylactic or empiric antifungal agents targeting Candida in critically ill non-neutropenic patients without transplant history 1.

Empirical Therapy

For persistent neutropenia with recurrent fever despite broad-spectrum antibacterials:

• Initiate empirical antifungal therapy
• Continue until clinical stabilization and normalization of microbiological/radiological findings 4
• Amphotericin B deoxycholate is recommended with close adverse event monitoring 2